BGF Invests $3M in ARuVR: Leveraging SEIS for Startup Growth
Discover how BGF’s $3 million investment in ARuVR utilizes the Seed Enterprise Investment Scheme to drive innovation in virtual and augmented reality learning.
Roam Local Raises £600K Through EIS & SEIS: A Tech Startup Success Story
Learn how Roam Local Limited successfully raised £600,000 under the EIS and SEIS schemes to fuel their digital high street marketing app.
Essential Guides for Investors: Navigating SEIS & EIS in the UK
Access our comprehensive guides tailored for investors to effectively navigate and benefit from SEIS and EIS investment opportunities in the UK.
PlayFund Launches: A New High-Return Investment Scheme in the Gaming Industry
Discover PlayFund, the latest investment scheme offering up to 250% returns within three years for investors in the gaming sector.
Are Changes to Funding Schemes Revolutionizing UK Startup Investments?
Analyze the recent changes to funding schemes and their impact on the UK startup ecosystem and investment opportunities.
Leveraging SEIS & EIS Grants for Business Expansion in the UK
Discover how SEIS and EIS grants can help your UK business expand by providing tax reliefs to investors and raising essential finance.
How the Enterprise Investment Scheme (EIS) Facilitates Funding for High-Risk UK Businesses
Explore the Enterprise Investment Scheme (EIS) and how it provides tax reliefs to investors supporting high-risk trading companies in the UK.
Maximizing Early-Stage Funding with the Seed Enterprise Investment Scheme (SEIS)
Learn how the Seed Enterprise Investment Scheme (SEIS) offers tax incentives and funding benefits for early-stage startups and investors in the UK.
O2H Human Health SEIS Fund: Supporting Innovative Biotech Startups
Learn how the O2H Human Health SEIS Fund backs UK biotech startups through SEIS, focusing on innovative drug discovery and artificial intelligence technologies.
Investing in Biotech: The O2H Human Health SEIS Fund Portfolio
Explore the O2H Human Health SEIS Fund and its investments in the UK’s early-stage biotech companies specializing in drug discovery and AI technologies.